Clinical Research Directory
Browse clinical research sites, groups, and studies.
Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)
Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Summary
Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.
Key Details
Gender
MALE
Age Range
30 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-04-01
Completion Date
2025-11-01
Last Updated
2025-10-02
Healthy Volunteers
No
Conditions
Interventions
PRP injection
3 ML OF PRP
Alprostadil 20 micrograms
1 ML
Locations (1)
Policlinico di Bari - Azienda Ospedaliero Universitaria Consorziale Policlinico
Bari, Italy